We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
May 4th, 2021 On April 15, 2021 the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for type 1 diabetes (T1D). This designation is intended to expedite the development and review of drugs for serious and life-threatening conditions. TTP399 is a liver-selective glucokinase (or GK) […]
April 19, 2021 JDRF was founded over 40 years by a group of devoted parents to provide a voice for the type 1 diabetes (T1D) community – and with the ultimate goal of finding a cure for T1D so that their children and all those who came after could know a world free from the […]
April 9, 2021 Volunteers can often be unsung heroes of an organization, but they help drive a mission forward with unparalleled dedication and perseverance, especially the volunteers at JDRF. And we couldn’t be more excited and honoured to recognize some of our incredible volunteers who always go above and beyond for the type 1 diabetes […]
100 years after the discovery of insulin, JDRF is pleased to announce the results of the first annual Beyond Insulin Vote for Research.
JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out to do and are able to help drive our mission forward – and this group includes regulators. JDRF recognizes the importance of engaging with regulators in order to to help shape and provide clear and reasonable pathways to scientific research and therapy approvals for T1D treatment and cure therapies.
JDRF’s mission of improving lives and curing type 1 diabetes (T1D) cannot be achieved alone. It requires us to engage with stakeholders who believe in what we have set out to do and are able to help drive our mission forward – and this group includes regulators. JDRF recognizes the importance of engaging with regulators […]
Halloween day will never be the same for Conrad Pow as that was the day in 2018 when his daughter Chloe was diagnosed with type 1 diabetes (T1D).
This past month, as part of JDRF’s #AccessforAll campaign, British Columbians impacted by type 1 diabetes (T1D) came together with patient advocates, clinicians and elected officials to discuss the benefits of continuous glucose monitoring (CGM) and flash glucose monitoring (Flash GM) devices, and the need to cover these technologies under B.C. Pharmacare.
Our #AccessForAll campaign has been keeping busy, finding new and creative ways to advocate government officials at the provincial level despite the constraints of COVID-19. To everyone who has supported by volunteering time, talents or donations– thank you.
March 8 marks International Women’s Day (IWD) globally. This 2021 campaign theme is #ChooseToChallenge.
For anyone impacted by type 1 diabetes (T1D), the term ‘biosimilars’ is one that will become increasingly familiar now that the patents of some biologic insulins are expiring. This means that biosimilar versions of these insulins may be approved, and some are already on the North American market.
Like most parents after their child has been diagnosed with Type 1 diabetes, Cindy Voss found herself overwhelmed, anxious and exhausted. With an active 10-year old whose glucose levels would drop quickly and unexpectedly, Cindy found herself constantly worrying and would get up every couple of hours throughout the night to prick her son Mathew’s finger to get a blood sugar reading.
Notifications
